Support worst-case product selection
Worst-case selection needs a scientific rationale and assessment of new products.
CV-REQ-000004
EU GMP Annex 15: Qualification and Validation§ 10.10
TOPIC EXPLORER
Worst Case
Selecting representative challenges and recording the limits of that representation.
6 connected references
Justify sampling locations
Protocols should identify sampling locations, their rationale and acceptance criteria.
CV-REQ-000006
EU GMP Annex 15: Qualification and Validation§ 10.11
Control time before cleaning
Residue drying can affect the effectiveness of a cleaning procedure.
CV-REQ-000012
Validation of Cleaning Processes§ Evaluation of cleaning validation
Reflect actual equipment use
Cleaning validation should reflect how equipment is actually used.
CV-REQ-000014
Q7A: Good Manufacturing Practice for APIs§ 12.7 — equipment usage
Address manual cleaning variability
Control operator-related variability in manual cleaning.
CV-REQ-000025
Cleaning validation guide (GUI-0028)§ 7.1.1
Assess new products before introduction
Evaluate new products within the existing cleaning control strategy.
CV-REQ-000026
Cleaning validation guide (GUI-0028)§ 7.3.2
Practical guidance
The State of Cleaning Validation 2026: Five Developments Reshaping the Field
Two years of regulatory revision, enforcement, new standards, tighter analytics and a first serious statistics stack have moved cleaning validation out of the appendix and into the centre of GMP. Five developments define where the field stands in September 2026 — and each one changes something a programme owner has to decide.
From Biologics to ADCs: Why New Modalities Are Changing Cleaning Validation
Biologics degrade under cleaning, ADCs split one residue into antibody, linker, payload and conjugate, and peptide APIs combine high potency with methods already under strain. A synthesis of the local evidence on why toxicology, cleaning and detectability now move together.
From Three Runs to Lifecycle Control: What Continued Cleaning Verification Really Means
The three-run cleaning validation was never a requirement — it was the convention that grew where guidance was silent. PI 006-4, the ASTM cleaning standards and three recent FDA warning letters all point at the same thing: what has to be maintained is a validated state, and continued cleaning verification is how you know it still holds.
PIC/S Publishes PI 006-4: A New Qualification and Validation Recommendation Takes Effect in October
PIC/S has published PI 006-4, the revised Recommendations on Qualification and Validation, superseding the 2007 PI 006-3 and entering into force on 1 October 2026. Cleaning validation now occupies a full chapter, with HBEL-driven scope, explicit limits on visual inspection and a clear position against continued test-until-clean practice.
What FDA Has Been Citing in Cleaning Validation: The Recurring Themes of 2025–2026
Twelve FDA warning letters issued between 3 December 2024 and 24 July 2026 cite cleaning and cross-contamination control. Read together rather than case by case, they stop looking like twelve incidents and start looking like one audit checklist: worst-case selection, hold times, recovery, MACO justification, visual-only strategies, sampling locations, change control and lifecycle management — in that order of frequency.
ADCs Are Creating a New Cleaning Validation Problem
Antibody-drug conjugates combine a biologic, a chemical linker and a cytotoxic payload on shared equipment. A STERIS webinar frames the problem; independent guidance shows why one product-specific assay no longer answers the question.
Worst Case or Product-Specific? New Research Reopens the Cleaning Validation Strategy Debate
A comparative review in the PDA Journal weighs worst-case matrices against product-specific validation and proposes a hybrid model anchored on visible residue limits.
EU and PIC/S Start the Next Revision of Annex 15 — What Validation Teams Should Watch
A joint EMA–PIC/S concept paper proposes extending Annex 15 to active substance manufacturers and aligning it with ICH Q9(R1). The current Annex 15 stays in force, and the earliest a revised text could be published is 2028.
Can a Cleaning Validation Demonstrate Reproducibility If Every Run Samples Somewhere Different?
FDA's Warning Letter 320-26-43 to Cosmetic Manufacturers (Aust) Pty Ltd. states that the firm's cleaning validation protocol 'was not designed to demonstrate reproducibility'. The cause is a design flaw that is easy to copy by accident: each qualification run sampled a different set of locations, so the runs were never replicates of the same measurement.
A Cleaning Verification Programme Is Only Useful If It Can Detect the Risk
FDA Warning Letter 320-26-40 to Cohance Lifesciences did not turn on a single residue number. It turned on whether the firm's verification programme could have found the carryover at all — and whether its worst-case basis was ever revisited.
When the Cleaning Validation No Longer Matches the Factory
FDA's December 2025 letter to Medinatura New Mexico records a firm acknowledging that its cleaning validation was not reflective of current operations after years of buying new equipment and adding new products. What the gap looks like from the inside — and what it asks of change control.
Cleaning Validation Is Becoming an Operational Strategy, Not Just a Compliance Exercise
A BeNeLux ISPE event on 23 September 2025 put 'business continuity' and 'culture' next to 'compliance' in the same talk title. That framing is the story: cleaning validation is being repositioned as an operational capability that keeps multi-product campaigns running, not a documentation obligation discharged before an inspection.
A Cleaning Validation Can Age: What Happens When Products Change but the Study Does Not
The FDA's August 2025 warning letter to ABBE Laboratories describes a 2009 cleaning validation still standing while a harder-to-clean product was introduced onto the same shared kettle — and no change-control step that caught it.
Can Cleaning Be Monitored in Real Time? In-Line UV Moves Validation Closer to PAT
A STERIS-authored article in Pharmaceutical Technology reports that in-line UV spectrometry at 220 nm can follow a biopharmaceutical cleaning cycle continuously, from heavily soiled rinse to baseline. The data are encouraging, the framing is vendor-supplied, and the distance between process monitoring and a release decision is where our own thinking has to do the work.
Should Cleaning Validation Extend Into the QC Laboratory?
A 2025 DARU Journal of Pharmaceutical Sciences study builds a structured cleaning-validation protocol for QC-lab glassware and stainless-steel equipment, using oxcarbazepine as worst-case API and pairing HPLC residue analysis with conductivity and TOC detergent checks.
When MACO Is Not Enough: What the Granules India Warning Letter Really Teaches
The FDA rejected a retrospective MACO argument in a February 2025 warning letter — not because the arithmetic was wrong, but because the cleaning it assumed had not been performed. What cleaning-validation teams can take from it.
FDA Again Links Shared Equipment to the Need for a Lifecycle Cleaning Programme
A December 2024 warning letter to Brands International Corporation cites the firm under 21 CFR 211.67(b) for failing to perform cleaning validation studies on non-dedicated equipment — and asks for a cleaning programme built around worst-case products, worst-case swab sites and maximum hold times before cleaning.
When Shared Equipment Has Never Been Cleaning-Validated: Lessons From an FDA Warning Letter
An FDA Warning Letter to Indian API manufacturer Micro Orgo Chem describes non-dedicated equipment that had never been cleaned under a validated procedure, cleaning SOPs that were not followed, and no evidence that the rinse and swab samples required by the firm's own procedure were ever collected or tested.
ASTM Puts Process Capability on the Cleaning Validation Agenda
ASTM work item WK92658 wants to standardise how cleaning processes are judged capable — one-sided limits, small data sets, non-normal residues and continued verification included. It is the statistical gap E3106 left open.
What Happens to Biologics During Cleaning? New Data on Cleaning-Induced Protein Degradants
A bench-scale study puts the 650 ug/dose parenteral PDE for cleaning-induced protein degradants to the test with human-cell immunogenicity assays on HLE BiTE and mAb degradants, spiked into the same and a cross product.